NCT04564040 - A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions

Mantle Cell LymphomaCOVID-19

Interventions

DRUG

Acalabrutinib Treatment A

Participants will receive 100 mg AT suspension in water via NG tube.

DRUG

Acalabrutinib Treatment B

Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.

DRUG

Acalabrutinib Treatment C

Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.

DRUG

Acalabrutinib Treatment D

Participants will receive 100 mg AT orally.

Trial Locations (1)

Research Site, Berlin